Imperial College London
Portrait Picture

ProfessorVictoriaCornelius

Faculty of Medicine, School of Public Health

Professor in Medical Statistics and Trials Methodology
 
 
 
//

Contact

 

+44 (0)20 7594 1218v.cornelius

 
 
//

Assistant

 

Mrs Ranjit Rayat +44 (0)20 7594 3445

 
//

Location

 

111Stadium HouseWhite City Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Munro:2021:10.1016/S0140-6736(21)02717-3,
author = {Munro, APS and Janani, L and Cornelius, V and Aley, PK and Babbage, G and Baxter, D and Bula, M and Cathie, K and Chatterjee, K and Dodd, K and Enever, Y and Gokani, K and Goodman, AL and Green, CA and Harndahl, L and Haughney, J and Hicks, A and van, der Klaauw AA and Kwok, J and Libri, V and Llewelyn, MJ and McGregor, AC and Minassian, AM and Moore, P and Mughal, M and Mujadidi, YF and Murira, J and Osanlou, O and Osanlou, R and Owens, DR and Pacurar, M and Palfreeman, A and Pan, D and Rampling, T and Regan, K and Saich, S and Salkeld, J and Saralaya, D and Sharma, S and Sheridan, R and Sturdy, A and Thomson, EC and Todd, S and Twelves, C and Read, RC and Charlton, S and Hallis, B and Ramsay, M and Andrews, N and Nguyen-Van-Tam, JS and Snape, MD and Liu, X and Faust, SN and COV-BOOST, study group},
doi = {10.1016/S0140-6736(21)02717-3},
journal = {The Lancet},
title = {Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial},
url = {http://dx.doi.org/10.1016/S0140-6736(21)02717-3},
volume = {398},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: Few data exist on the comparative safety and immunogenicity of different COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection of booster vaccines, we investigated the reactogenicity and immunogenicity of seven different COVID-19 vaccines as a third dose after two doses of ChAdOx1 nCov-19 (Oxford-AstraZeneca; hereafter referred to as ChAd) or BNT162b2 (Pfizer-BioNtech, hearafter referred to as BNT). METHODS: COV-BOOST is a multicentre, randomised, controlled, phase 2 trial of third dose booster vaccination against COVID-19. Participants were aged older than 30 years, and were at least 70 days post two doses of ChAd or at least 84 days post two doses of BNT primary COVID-19 immunisation course, with no history of laboratory-confirmed SARS-CoV-2 infection. 18 sites were split into three groups (A, B, and C). Within each site group (A, B, or C), participants were randomly assigned to an experimental vaccine or control. Group A received NVX-CoV2373 (Novavax; hereafter referred to as NVX), a half dose of NVX, ChAd, or quadrivalent meningococcal conjugate vaccine (MenACWY) control (1:1:1:1). Group B received BNT, VLA2001 (Valneva; hereafter referred to as VLA), a half dose of VLA, Ad26.COV2.S (Janssen; hereafter referred to as Ad26) or MenACWY (1:1:1:1:1). Group C received mRNA1273 (Moderna; hereafter referred to as m1273), CVnCov (CureVac; hereafter referred to as CVn), a half dose of BNT, or MenACWY (1:1:1:1). Participants and all investigatory staff were blinded to treatment allocation. Coprimary outcomes were safety and reactogenicity and immunogenicity of anti-spike IgG measured by ELISA. The primary analysis for immunogenicity was on a modified intention-to-treat basis; safety and reactogenicity were assessed in the intention-to-treat population. Secondary outcomes included assessment of viral neutralisation and cellular responses. This trial is registered with ISRCTN, number 73765130. FINDINGS: Between June 1 and June
AU  - Munro,APS
AU  - Janani,L
AU  - Cornelius,V
AU  - Aley,PK
AU  - Babbage,G
AU  - Baxter,D
AU  - Bula,M
AU  - Cathie,K
AU  - Chatterjee,K
AU  - Dodd,K
AU  - Enever,Y
AU  - Gokani,K
AU  - Goodman,AL
AU  - Green,CA
AU  - Harndahl,L
AU  - Haughney,J
AU  - Hicks,A
AU  - van,der Klaauw AA
AU  - Kwok,J
AU  - Libri,V
AU  - Llewelyn,MJ
AU  - McGregor,AC
AU  - Minassian,AM
AU  - Moore,P
AU  - Mughal,M
AU  - Mujadidi,YF
AU  - Murira,J
AU  - Osanlou,O
AU  - Osanlou,R
AU  - Owens,DR
AU  - Pacurar,M
AU  - Palfreeman,A
AU  - Pan,D
AU  - Rampling,T
AU  - Regan,K
AU  - Saich,S
AU  - Salkeld,J
AU  - Saralaya,D
AU  - Sharma,S
AU  - Sheridan,R
AU  - Sturdy,A
AU  - Thomson,EC
AU  - Todd,S
AU  - Twelves,C
AU  - Read,RC
AU  - Charlton,S
AU  - Hallis,B
AU  - Ramsay,M
AU  - Andrews,N
AU  - Nguyen-Van-Tam,JS
AU  - Snape,MD
AU  - Liu,X
AU  - Faust,SN
AU  - COV-BOOST,study group
DO  - 10.1016/S0140-6736(21)02717-3
PY  - 2021///
SN  - 0140-6736
TI  - Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial
T2  - The Lancet
UR  - http://dx.doi.org/10.1016/S0140-6736(21)02717-3
UR  - https://www.ncbi.nlm.nih.gov/pubmed/34863358
UR  - https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02717-3/fulltext
UR  - http://hdl.handle.net/10044/1/93014
VL  - 398
ER  -
Download